SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vivus: into single digits -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (85)2/16/1998 11:28:00 AM
From: Tunica Albuginea  Respond to of 1016
 
BigK, do you know how many patients with sickle cell disease ( prone to priapism with ED drugs; Vivus has a warning in it's insert )were included in the Viagra studies?I bet you none. I bet you they were actually studiously excluded. The subjects usually admitted in a study are those that are likely to give the best results. So far nobody know exactly, specifically, what kinds of patients were included in the Viagra studies. Their disease description is described as simply " organic ". There are at least 20 shades of gray in " organic ".

TA



To: BigKNY3 who wrote (85)2/16/1998 5:51:00 PM
From: Cacaito  Respond to of 1016
 
BigKNY3, Sildenafil will have a warning for Sickle cell patients. These patients are rightly excluded in any study of pro-erection drugs, their disease predispose them to priapism which is one of the complications of the "sickling" crisis with thromboembolism inside the corpora cavernosa blood vessels.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News